Zanubrutinib with chemotherapy for newly diagnosed brain lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of primary central nervous system lymphoma (a lymphoma that starts in the brain or spinal cord).
- You must not have received any treatment for this lymphoma yet.
- You must be in generally good health, with adequate kidney, liver, and heart function.
- You must be willing to use effective birth control during the study and for 30 days after the last dose, if you are of childbearing potential.
- You must not have other active cancers, serious infections, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests selinexor given together with methotrexate and rituximab to treat lymphoma that has returned or not responded in the brain. It may help by attacking cancer cells in the central nervous system (brain/spinal fluid) after prior treatment.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Hear when a new Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.